[1] |
YAO Yao, XIA Min, HOU Cong, HE Airong.
Effects of ABT-737 on the growth and angiogenesis of ovarian cancer cells in the co-culture of TAMs and SKOV3 cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 144-153.
|
[2] |
YUE Ling, DU Junhong, LIU Xiao, LI Yulan, XU Feixue.
Mechanisms of histone methylation and acetylation modifying enzymes in ovarian cancer and therapeutic advances
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1299-1306.
|
[3] |
FANG Chuanchuan, NI Guantai, JIN Lan, LIU Ji, LIU Xiaoqing, QIAO Chun, LUO Yonghong.
Correlation between phosphorylation of PEA-15-Ser104 site and prognosis of epithelial ovarian cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 523-528.
|
[4] |
QI Bingli, HUANG Ping, YAN Ruixue, LI Qian.
Study on effects of naringenin on inhibiting proliferationand invasion of ovarian cancer cells and inducing apoptosis by PI3K/AKT/NF-κB pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1234-1241.
|
[5] |
SUN Hongya, YUAN Aijuan, LI Jipeng.
Inhibitory effect of juglone on proliferation and invasion of human ovarian cancer SKOV3 and IOSE80 cells and its mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 32-37.
|
[6] |
CHEN Xiangyan, CHEN Cong, SUN Yun, ZHANG Hong, GAO Chuchu, CHEN Shu.
Effects of Yishen Kangliu recipe in combination with IL-2 peritoneal perfusion in treatment of ovarian cancer-associated ascites
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1408-1414.
|
[7] |
TONG Yuehong, SHAO Mingjun, HU Min, HU Meixu, ZHANG Lin, ZHU Pengfei.
Expression of UTP23 gene in epithelial ovarian cancer paclitaxel resistant cells and its effect on paclitaxel resistance to chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 654-658.
|
[8] |
FU Jun, YE Da-feng, FU Yun-feng.
Proteomics study on paclitaxel-resistant ovarian cancer subline
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 525-530.
|
[9] |
HU Xin, SONG Shu-hui, XIONG Yu-qing, CAI Li-ping.
Effects of Naringin on expression of p38MAPK and ERK1/2 signaling proteins of Human ovarian cancer cell line SKOV3
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(5): 519-523.
|
[10] |
SONG Shu-hui, HU Xin, XIONG Yu-qing, CAI Li-ping.
Effects of Naringin on expression of COX-2 mRNA and protein in Human ovarian cancer cell line SKOV3
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 271-275.
|
[11] |
XU Lin-lin, SUN Qing-min, LUO Xuan, ZHAI Su-lan, LI Ping, ZHAO Xiao-mei, WANG Xue-rong.
Effects of genistein on the growth of ovarian cancer cell SKOV3 by regulating miR-27a and target gene expression
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(12): 1321-1326.
|
[12] |
CHEN Li, HUO Guan-hua, LV Yao-feng, ZHANG Qin.
Proliferation inhibition and apoptosis induction in human ovarian cancer SKOV3 cells by Cpd5
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(10): 1121-1127.
|
[13] |
PAN Fang-fang, ZHOU Yong-mei, ZHANG Min, SONG Jun-na, LIU Bao-lin.
Luteolin ameliorates endothelial dysfunction induced by oxidative stress
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(4): 418-424.
|
[14] |
HOU Shu-guang, LIN Sen, YU Bo, JIN Ling-ling, YANG Hong.
Luteolin activates the cystic fibrosis transmembrane conductance regulator chloride channel
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(3): 249-253.
|
[15] |
TANG Ning, LI Zi-yan, ZHOU Yong-mei, LIU Bao-lin.
Evaluation of anti-inflammatory effects of luteolin and underlying mechanisems
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 195-199.
|